PCT and MR-proADM
Utility to support decision making during COVID-19 and beyond
September 17, 2020, 11:45-12:30 CET
This symposium provides insights into the practical implementation of both biomarkers in the real-life management of COVID-19 patients.
- Gain an understanding of the utility of Procalcitonin in the early identification of COVID-19 patients at low risk of bacterial coinfection and adverse outcomes.
- Get to know new data on the prognostic significance of MR-proADM measured through hospital admissions of COVID-19 patients.
- Go beyond COVID-19 and be the first to learn about the results of the interventional trial IDEAL and how MR-proADM can improve discharge decisions.
Presentations:
Clinical utility of procalcitonin in the management of COVID-19 patients
Michael K. Mansour, Massachusetts General Hospital, Boston, USA
Prognostic significance of MR-proADM admission levels in COVID-19 patients
Philipp Schuetz, Medizinische Universitätsklinik, Kantonsspital Aarau, Switzerland
Improving discharge in the ED: identifying patients with suspicion of infection in the ED who have low disease severity using MR-proADM
Juan González del Castillo, Hospital Clínico San Carlos, Madrid, Spain
- Live Q & A
